DNA Diagnostics Market Size To Reach $14.14 Billion By 2030

DNA Diagnostics Market Growth & Trends

The global DNA diagnostics market size is expected to reach a value of USD 14.14 billion by 2030, growing at a CAGR of 4.14% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is due to advancements in genome sequencing and the development of personalized DNA-level diagnostic applications. In addition, the rising number of government-sponsored patented research initiatives and funded projects are anticipated to further drive demand in the market. For instance, in December 2022, the UK government announced a funding of USD 229.4 (£175) million for the development and creation of advanced genomic research.

The market growth is highly driven by the introduction of novel technologies for genome profiling. Moreover, with the increasing incidence of chronic oncology and infectious diseases that rely on DNA prototyping for treatment and diagnosis through personalized medicine, the demand for DNA diagnostics/testing-based research is anticipated to increase significantly over the forecast period. Furthermore, the increasing demand for DNA diagnostics/testing is driven by the rising demand for prenatal testing, and in-vitro fertilization is expected to provide positive growth prospects to the market. In September 2022, Eurofins Genoma announced the launch of niPGT-A, an embryo-free, non-invasive preimplantation screening test.

DNA diagnostics enables the comprehensive analysis of tumor genomes through techniques such as next-generation sequencing (NGS). NGS allows for the simultaneous sequencing of multiple genes, providing a detailed view of the genetic alterations present in the tumor. By comparing the tumor genome with normal tissue DNA, scientists and clinicians can identify specific mutations, copy number variations, and structural rearrangements unique to the cancer cells. In June 2022, Illumina, a DNA sequencing and array-based technology provider, introduces a research test developed in collaboration with Merck, aimed at unlocking deeper insights into the tumor genome.

Hepatitis C virus (HCV) is a global health concern, affecting millions of people worldwide. Accurate and timely diagnosis of HCV is crucial for effective treatment and prevention of further transmission. In this context, DNA diagnostics has emerged as a powerful tool for detecting and managing HCV infections. In July 2022, Roche introduced a groundbreaking dual antigen and antibody diagnostic test Elecsys HCV Duo, to aid the global efforts in eradicating the hepatitis C virus.

 Request a free sample copy or view report summary: DNA Diagnostics Market Report

DNA Diagnostics Market Report Highlights

• Based on technology, PCR-based diagnostics dominated the market in 2022 with a revenue share of 50.03% due to its extensive market usage and the wide availability of products

• The NGS-based diagnosis segment is expected to grow at the fastest CAGR of 7.98% during the forecast period owing to the development of innovative and breakthrough advancements in the market. NGS platforms can process multiple samples in parallel, allowing for high-throughput sequencing

• Based on application, the cancer genetics tests segment dominated the market in 2022 with a revenue share of 29.58% owing to the increase in disease outbreaks over the years

• In terms of region, North America dominated the market in 2022 with a revenue share of 42.45%, which is attributed to several key factors, such as the presence of advanced healthcare infrastructure and robust government initiatives

• Asia Pacific is expected to grow exponentially over the forecast period at the fastest CAGR of 6.23% owing to the growing R&D initiatives provided by governments in developing economies like China and India

DNA Diagnostics Market Segmentation

Grand View Research has segmented the global DNA diagnostics market based on technology, application, and region:

DNA Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Microarrays-based Diagnostics

• PCR-based Diagnostics

• In-situ Hybridization Diagnostics

• NGS DNA Diagnosis

DNA Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer Genetics Tests

• Infectious Diseases DNA Testing

  • HBV Diagnostic

  • HCV Diagnostic

  • HIV Diagnostic

  • TB Diagnostic

  • CT/NG Diagnostic

  • HPV Diagnostic

  • MRSA Diagnostic

  • Others

• Newborn Genetic Screening

• Preimplantation & Reproductive Diagnosis

• Non-Infectious Diseases DNA Testing

  • Cardiovascular Diseases

  • CNS & PNS Related

  • Skeletal, Connective, Ectodermal & Dermal DNA Testing

  • Lung, Kidney, Liver & GT Related

  • Sensory Diseases

• Prenatal DNA Carrier Screening

• Pharmacogenomics/Drug Metabolism

• Hematology & Immunology/Identity Diagnostics & Forensics

• Others

DNA Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the DNA Diagnostics Market

• GE Healthcare

• Abbott

• Beckman Coulter Inc.

• Bio-Rad Laboratories, Inc.

• Thermo Fisher Scientific Inc.

• Illumina Inc.

• Cepheid.

• Hologic, Inc.

• Siemens Healthcare GmbH

• F. Hoffmann-La Roche

• QIAGEN

• Agilent Technologies Inc.